Shares of Akcea Therapeutics, Inc. (NASDAQ:AKCA) have been given an average broker rating score of 1.00 (Strong Buy) from the four analysts that provide coverage for the stock, Zacks Investment Research reports. Four equities research analysts have rated the stock with a strong buy rating.

Analysts have set a 12 month consensus price objective of $24.00 for the company, according to Zacks. Zacks has also given Akcea Therapeutics an industry rank of 109 out of 265 based on the ratings given to its competitors.

A number of research analysts have commented on the company. Stifel Nicolaus assumed coverage on Akcea Therapeutics in a research report on Tuesday, August 8th. They issued a “buy” rating and a $19.00 price objective on the stock. BMO Capital Markets started coverage on Akcea Therapeutics in a research report on Tuesday, August 8th. They issued an “outperform” rating and a $25.00 price objective on the stock. Wells Fargo & Company started coverage on Akcea Therapeutics in a research report on Tuesday, August 8th. They issued an “outperform” rating and a $27.00 price target on the stock. Cowen Inc started coverage on Akcea Therapeutics in a research report on Tuesday, August 8th. They issued an “outperform” rating on the stock. Finally, Zacks Investment Research upgraded Akcea Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, November 9th.

Several large investors have recently bought and sold shares of AKCA. Granahan Investment Management Inc. MA bought a new position in shares of Akcea Therapeutics in the 3rd quarter worth $8,528,000. OxFORD Asset Management LLP bought a new position in shares of Akcea Therapeutics in the 3rd quarter worth $6,872,000. Candriam Luxembourg S.C.A. bought a new position in shares of Akcea Therapeutics in the 3rd quarter worth $5,314,000. Schwab Charles Investment Management Inc. bought a new position in shares of Akcea Therapeutics in the 3rd quarter worth $1,654,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Akcea Therapeutics in the 3rd quarter worth $1,413,000. Institutional investors and hedge funds own 19.15% of the company’s stock.

Akcea Therapeutics (NASDAQ AKCA) opened at $18.69 on Friday. Akcea Therapeutics has a 12-month low of $8.10 and a 12-month high of $31.23.

COPYRIGHT VIOLATION NOTICE: This story was originally published by American Banking News and is owned by of American Banking News. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://www.americanbankingnews.com/2017/11/25/zacks-akcea-therapeutics-inc-akca-receives-consensus-recommendation-of-strong-buy-from-brokerages.html.

About Akcea Therapeutics

Akcea Therapeutics, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company’s drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc (Ionis).

Get a free copy of the Zacks research report on Akcea Therapeutics (AKCA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Akcea Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akcea Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.